Obrixtamig Clinical Trials (2026): 5 Studies for Extensive-stage Small Cell Lung Cancer (ES-SCLC) & Extrapulmonary Neuroendocrine Cancer
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
5 Obrixtamig clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 5 indications (including Extensive-stage Small Cell Lung Cancer (ES-SCLC) & Extrapulmonary Neuroendocrine Cancer) and 1,480 total planned enrollment. 2 Phase 3 Obrixtamig trials and 1 Phase 2 are listed. 4 Obrixtamig clinical trials are actively recruiting at 3 U.S. sites across 3 states. Most recent activity: NCT07561645 (Apr 2032).
Where to Participate: All Obrixtamig Trial Sites in the U.S. (3 sites across 3 states)
Every actively recruiting Obrixtamigtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| GA | Winship Cancer Institute | Atlanta30322 | NCT04429087 | Map |
| MD | University of Maryland School of Medicine | Baltimore21201 | NCT04429087 | Map |
| MO | Washington University School of Medicine | St Louis63108 | NCT04429087 | Map |
Obrixtamig clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | not yet recruiting | Total |
|---|---|---|---|---|
| P1 | 1 | 1 | 2 | |
| P2 | 1 | 1 | ||
| P3 | 1 | 1 | 2 |
Recruiting Obrixtamig clinical trials (4)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07561645 | ALPINE 2A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung | P2 | Large Cell Neuroendocrine Carcinoma of the Lung | 75 | Jul 2026 |
| NCT07544654 | DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy | P3 | Extrapulmonary Neuroendocrine Cancer | 390 | Jun 2026 |
| NCT07472517 | DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy | P3 | Small Cell Lung Cancer (SCLC) | 670 | Apr 2026 |
| NCT04429087 | A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 | P1 | Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3 | 300 | Jul 2020 |
Obrixtamig clinical trials by indication
Large Cell Neuroendocrine Carcinoma of the Lung (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07561645 | ALPINE 2 | P2 | not yet recruiting | A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung |
Extrapulmonary Neuroendocrine Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07544654 | — | P3 | not yet recruiting | DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy |
Small Cell Lung Cancer (SCLC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07472517 | — | P3 | recruiting | DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy |
Small Cell Lung Carcinoma (SCLC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05879978 | BI 764532 | P1 | active not recruiting | A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 |
Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04429087 | — | P1 | recruiting | A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 |
Obrixtamig pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| ALPINE 2 | NCT07561645 | P2 | not yet recruiting | Large Cell Neuroendocrine Carcinoma of the Lung | 75 | — |
All Obrixtamig trials (5)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07561645 | ALPINE 2 | A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung | P2 | not yet recruiting | 75 | Technische Universität Dresden | Jul 2026 |
| NCT07544654 | DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy | P3 | not yet recruiting | 390 | Boehringer Ingelheim | Jun 2026 | |
| NCT07472517 | DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy | P3 | recruiting | 670 | Boehringer Ingelheim | Apr 2026 | |
| NCT04429087 | A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 | P1 | recruiting | 300 | Boehringer Ingelheim | Jul 2020 | |
| NCT05879978 | BI 764532 | A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 | P1 | active not recruiting | 45 | Boehringer Ingelheim | Jun 2023 |
Obrixtamig clinical trials: frequently asked questions
- How many Obrixtamig clinical trials are there?
- 5 Obrixtamig clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are actively recruiting participants.
- Are Obrixtamig clinical trials recruiting in 2026?
- Yes — 2 Obrixtamig trials are actively recruiting in 2026, with 3 U.S. sites across 3 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Obrixtamig being studied for?
- Obrixtamig is being studied for Extensive-stage Small Cell Lung Cancer (ES-SCLC), Extrapulmonary Neuroendocrine Cancer, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Neoplasms, Small Cell Lung Cancer (SCLC) and 2 more. The trials are grouped by indication on this page.
- What phase is Obrixtamig in?
- Obrixtamig clinical trials span 2 Phase 3, 1 Phase 2, 2 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Obrixtamig clinical trials?
- The lead sponsor across the most Obrixtamig trials is Boehringer Ingelheim, with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Obrixtamigas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: